文献类型：期刊文献

英文题名：A yigP mutant strain is a small colony variant of E. coli and shows pleiotropic antibiotic resistance

作者：Xia, Hui[1];Tang, Qiongwei[1];Song, Jie[1];Ye, Jiang[1];Wu, Haizhen[1,2];Zhang, Huizhan[1,2]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai, Peoples R China;[2]East China Univ Sci & Technol, Dept Appl Biol, Shanghai, Peoples R China

年份：2017

卷号：63

期号：12

起止页码：961

外文期刊名：CANADIAN JOURNAL OF MICROBIOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000415361600004)】；

基金：This work was supported by the National Natural Science Foundation of China (31070073, 31372550, and 3120026).

语种：英文

外文关键词：Escherichia coli; small colony variants; yigP locus; microbial resistance; collateral sensitivity

摘要：Small colony variants (SCVs) are a commonly observed subpopulation of bacteria that have a small colony size and distinctive biochemical characteristics. SCVs are more resistant than the wild type to some antibiotics and usually cause persistent infections in the clinic. SCV studies have been very active during the past 2 decades, especially Staphylococcus aureus SCVs. However, fewer studies on Escherichia coli SCVs exist, so we studied an E. coli SCV during an experiment involving the deletion of the yigP locus. PCR and DNA sequencing revealed that the SCV was attributable to a defect in the yigP function. Furthermore, we investigated the antibiotic resistance profile of the E. coli SCV and it showed increased erythromycin, kanamycin, and D-cycloserine resistance, but collateral sensitivity to ampicillin, polymyxin, chloramphenicol, tetracycline, rifampin, and nalidixic acid. We tried to determine the association between yigP and the pleiotropic antibiotic resistance of the SCV by analyzing biofilm formation, cellular morphology, and coenzyme Q (Q(8)) production. Our results indicated that impaired Q(8) biosynthesis was the primary factor that contributed to the increased resistance and collateral sensitivity of the SCV. This study offers a novel genetic basis for E. coli SCVs and an insight into the development of alternative antimicrobial strategies for clinical therapy.